Active, not recruitingPhase 3NCT02767804
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xcovery Holdings, Inc.
- Principal Investigator
- Giovanni Selvaggi, MD, M.DCEO
- Intervention
- X-396 (ensartinib)(drug)
- Enrollment
- 290 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2025
Study locations (30)
- Moffitt Cancer Center, Tampa, Florida, United States
- University Cancer & Blood Center, Athens, Georgia, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Providence Portland Medical Center, Portland, Oregon, United States
- Sanatorio Parque S.A., Rosario, Argentina
- Border Medical Oncology Research Unit, Albury, New South Wales, Australia
- Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
- Chris O Brien Lifehouse, Camperdown, Australia
- Catholic University of Louvain (UCL) - Site Mont Godinne, Yvoir, Belgium
- Instituto do Câncer do Estado de São Paulo, São Paulo, São Paulo, Brazil
- Hospital de Câncer de Barretos - Fundação Pio XII, São Paulo, São Paulo, Brazil
- Hospital Haroldo Juaçaba - Instituto do Cancêr do Ceará, Fortaleza, Brazil
- Fundacao do ABC Faculdade de Medicina do ABC, São Paulo, Brazil
- Infirmière recherche Clinique, IUCPQ, Québec, Quebec, Canada
- Anhui Provincial Hospital, Hefei, Anhui, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02767804 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →